InvestorsHub Logo

andy55q

11/14/13 5:39 PM

#4595 RE: philife #4594

DARPA Battelle info-FYI
CytoSorbents Corporation (OTCBB: CTSO)
2013 Third Quarter Earnings Conference Call Transcript
November 6, 2013 @ 4:15 pm Eastern
What is the status of the DARPA program?
Regarding the DARPA program, we started our second year award, and we were recently
approached by Battelle, DARPA’s system integrator, to accelerate our development program so
they can integrate CytoSorb’s technology into early animal studies. We really view this as a very
positive endorsement of CytoSorbents’ technology, and look forward to continuing refinement
of the polymer technology in line with DARPA’s program milestones. We also just came back
from a DARPA principal investigator meeting, where we presented our progress, and we’re
really excited about how our technology complements those from other technology providers and how it seems to be all be coming together at this point.

ANESRI

11/14/13 8:45 PM

#4596 RE: philife #4594

I have always had this question about the assays - are these are exosomal assays? The issue is that there are so many new assays in the market for the same oncology conditions which are mentioned at various times in the AEMD PRs that one wonders what shall be the advantage of the assays offered by AEMD.

Also, why a new assay in the saturated field of HIV? This is just a straight question. A few years back there was a PR from AEMD about research with Morehouse School of Medicine about NEF proteins being transported in exosomes - any update?


ANESRI

11/17/13 12:26 PM

#4600 RE: philife #4594

Philife,

I was wondering why Dr. T wants the brain injury test to be "more specific " as opposed to more sensitive. I realized that it does make sense for sports, because if you can get quick results and the test is negative, the player can be on the field again and not miss the rest of the game. Again, depends on how quick is the test and how specific.

At the opening, did anyone mention about the patent AEMD holds for exosomes. It seems like a very broad patent - seems like it comes into play every time exosomes are removed from the body! If true, that by itself can be a huge revenue source for the company.